Koolmon Pharmaceutical Private Limited
About Koolmon Pharmaceutical Private Limited
Data last updated:
Koolmon Pharmaceutical Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 06 November 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U51397PN2020PTC195761.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Kuldeep Mahendra Khalate and Monika Kuldeep Khalate.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Lotuse Apartment Flat No – 16 Bldg No – A2 B Wing S.No 3/1/1/2 To 4 Yewalewadi, Pune, Maharashtra, India – 411048.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.23 Lakh, a decline of 62% compared to the previous year. For the same year it recorded a net profit of ₹134 (net margin 0.1%) and EBITDA of ₹71,055 (EBITDA margin 31.8%). Revenue has grown at a compounded annual rate (CAGR) of 20% over three years.
As per MCA filings, the company has open charges of ₹6 Lakh on record.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressLotuse Apartment Flat No – 16 Bldg No – A2 B Wing S.No 3/1/1/2 To 4 Yewalewadi, Pune, Maharashtra, India – 411048
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Koolmon Pharmaceutical Private Limited
The main business activity of Koolmon Pharmaceutical is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Koolmon Pharmaceutical Private Limited FY 2025 filings available
Koolmon Pharmaceutical Private Limited reported revenue of ₹2.23 Lakh (down 62% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Koolmon Pharmaceutical Private Limited
Revenue fell 62% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 20%. EBITDA fell 19% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Koolmon Pharmaceutical Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹71,055 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹134 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Koolmon Pharmaceutical Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 31.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Koolmon Pharmaceutical are in the company report.
Financial statements from FY 2021
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Koolmon Pharmaceutical Private Limited
Koolmon Pharmaceutical Private Limited is compared with the companies closest to it by revenue in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Techaro Innov Private Limited | ₹2.46 Lakh (FY 2025) | •••• | •••• | •••• | Hyderabad, Telangana, India | |
| Takshil Bio Pharma Private Limited | ₹2.44 Lakh (FY 2025) | •••• | •••• | -80.0% | •••• | Chandigarh, India |
| Mahaveer Surgicals Private Limited | ₹2.39 Lakh (FY 2025) | •••• | •••• | •••• | Bengaluru, Karnataka, India | |
| Medi-Marque Lab Private Limited | ₹2.34 Lakh (FY 2024) | •••• | •••• | -27.0% | •••• | Raigarh, Maharashtra, India |
| Kra Healthcare (OPC) Private Limited | ₹2.24 Lakh (FY 2025) | •••• | •••• | -27.0% | •••• | Delhi, India |
| Koolmon Pharmaceutical Private Limited this company | ₹2.23 Lakh (FY 2025) | •••• | •••• | -62.0% | •••• | Pune, Maharashtra, India |
| Hygeia Bio Science Private Limited | ₹2.18 Lakh (FY 2025) | •••• | •••• | 1184.0% | •••• | Chennai, Tamil Nadu, India |
| Care and Sure Biotech Private Limited | ₹2.17 Lakh (FY 2025) | •••• | •••• | •••• | Kadma, Jharkhand, India | |
| Dapcure Pharmaceutical Private Limited | ₹2.14 Lakh (FY 2022) | •••• | •••• | •••• | Pune, Maharashtra, India | |
| Dr. Pande's Med. Remedies (OPC) Private Limited | ₹2.06 Lakh (FY 2025) | •••• | •••• | -26.0% | •••• | Amrvatai, Maharashtra, India |
| Sap Medicare (OPC) Private Limited | ₹2.01 Lakh (FY 2025) | •••• | •••• | •••• | Palanpur, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Koolmon Pharmaceutical by revenue in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Koolmon Pharmaceutical Private Limited
Koolmon Pharmaceutical has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kuldeep Mahendra Khalate | Director | 06 Nov 2020 | 5 Years 11 Months | Current |
| Monika Kuldeep Khalate | Director | 06 Nov 2020 | 5 Years 11 Months | Current |
Charges & Borrowings of Koolmon Pharmaceutical Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 May 2024 | State Bank of India | ₹6 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Koolmon Pharmaceutical Private Limited
Employment history and EPFO contributions of people linked to Koolmon Pharmaceutical.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Koolmon Pharmaceutical Private Limited
Koolmon Pharmaceutical Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Kuldeep Mahendra Khalate was appointed as Director on 06 Nov 2020.
Credit Ratings, Litigation & Regulatory Alerts for Koolmon Pharmaceutical Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Koolmon Pharmaceutical Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Koolmon Pharmaceutical Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Koolmon Pharmaceutical Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Koolmon Pharmaceutical Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Koolmon Pharmaceutical Private Limited
Koolmon Pharmaceutical is an active private limited company based in Pune, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 06 November 2020 (6+ years old) and is registered under CIN U51397PN2020PTC195761.
Koolmon Pharmaceutical reported revenue of ₹2.23 Lakh for FY 2025 (down 62% YoY).
Koolmon Pharmaceutical has 2 current directors:
- Kuldeep Mahendra Khalate - Director
- Monika Kuldeep Khalate - Director
Koolmon Pharmaceutical reported a net profit of ₹134 (net margin 0.1%) and EBITDA of ₹71,055 (EBITDA margin 31.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Koolmon Pharmaceutical is 20% over three years. In the latest year (FY 2025) revenue fell 62%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Koolmon Pharmaceutical is U51397PN2020PTC195761. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Koolmon Pharmaceutical was incorporated on 06 November 2020, making it 6+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Koolmon Pharmaceutical by revenue are Techaro Innov Private Limited, Takshil Bio Pharma Private Limited, Mahaveer Surgicals Private Limited, Medi-Marque Lab Private Limited, Kra Healthcare (OPC) Private Limited and 5 more, all in the same principal business activity (Manufacture of basic pharmaceutical products and pharmaceutical preparations).
Kuldeep Mahendra Khalate was appointed as Director on 06 Nov 2020. Monika Kuldeep Khalate was appointed as Director on 06 Nov 2020.
The registered office of Koolmon Pharmaceutical is at Lotuse Apartment Flat No – 16 Bldg No – A2 B Wing S.No 3112 To 4 Yewalewadi, Pune, Maharashtra, India – 411048.
Koolmon Pharmaceutical has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh.